Clomipramine/sildenafil
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Clomipramine/sildenafil (developmental code name CDFR-0812) is a combination of the tricyclic antidepressant (TCA) and serotonin–norepinephrine reuptake inhibitor (SNRI) clomipramine and the phosphodiesterase PDE5 inhibitor and erectile dysfunction drug sildenafil which is under development for the on-demand treatment of premature ejaculation.[1][2][3] It is taken orally.[1] The drug is under development by CTCBIO.[1][2] As of October 2025, it is in phase 3 clinical trials in South Korea.[1][2]
ClomipramineTricyclic antidepressant (TCA), serotonin–norepinephrine reuptake inhibitor (SNRI), other actions
Other namesCDFR-0812; CDFR0812
| Combination of | |
|---|---|
| Clomipramine | Tricyclic antidepressant (TCA), serotonin–norepinephrine reuptake inhibitor (SNRI), other actions |
| Sildenafil | Phosphodiesterase PDE5 inhibitor |
| Clinical data | |
| Other names | CDFR-0812; CDFR0812 |
| Routes of administration | Oral[1] |
